Glaucoma is sometimes called the “silent thief of sight
” because it can cause irreparable damages to the eye before any symptom of visual impairment is perceived.
Glaucoma is the second leading cause of blindness globally, after cataract, according to WHO data, and it represents an even greater public health challenge than cataract because the blindness it causes is irreversible. Read about Glaucome on the WHO website at this link
The term “glaucoma”’ relates to a group of pathologic conditions characterized by optic nerve damage and visual field loss, secondary to retinal ganglion cell damage and cell death.
The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG).
READ MORE about Glaucoma
SIFI provides the ophthalmologists and their patients with a range of specialty pharmaceuticals, available as eye drops, for the medical treatment of glaucoma and ocular hypertension.
The active ingredients include beta-blockers (carteolol) and fixed combinations of beta-blockers with prostaglandins or carbonic anhydrase inhibitors (latanoprost/timolol; dorzolamide/timolol).